You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The tender offer period finished with around 92 percent of Beckman Coulter shareholders tendering their shares.
Danaher commenced a subsequent offering period set to expire on June 29, after which it expects to complete its purchase of Beckman Coulter.
The European Commission approved the deal, clearing the way for Danaher to complete the $6.8 billion purchase by the end of the month.
President and CEO J. Robert Hurley is now also interim Diagnostic Division President, while Scott Atkins was named president of the Life Science Division.
The company said that it anticipates regulatory approval from the European Commission on or about June 16 and to close the acquisition by the end of the month.
The company's Clinical Diagnostics segment was up 3 percent year over year, while Life Science slid 11 percent.
The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.
The deadline for the deal has been pushed back to April 27 from March 23.
In a research note, Jon Groberg wrote that in the near term firms with a larger consumables presence in Japan face greater revenue risk, while instrument firms face greater mid-term risk.
The firms have said they expect to complete the transaction in the first half of this year.
Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.
An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.
Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.
In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.